
Sign up to save your podcasts
Or
Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.
4.3
1616 ratings
Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.
14,188 Listeners
135 Listeners
315 Listeners
40 Listeners
497 Listeners
25,782 Listeners
57 Listeners
3,316 Listeners
55,899 Listeners
1,103 Listeners
45 Listeners
31 Listeners
7,982 Listeners
5,989 Listeners
170 Listeners